Adverum Biotechnologies (ADVM)
(Real Time Quote from BATS)
$9.45 USD
+0.06 (0.64%)
Updated Apr 26, 2024 01:02 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ADVM 9.45 +0.06(0.64%)
Will ADVM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADVM
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
How Adverum (ADVM) Stock Stands Out in a Strong Industry
Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround
Other News for ADVM
Adverum Biotechnologies management to meet with Truist
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
12 Health Care Stocks Moving In Tuesday's After-Market Session
Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)
Wall Street Analysts Are Bullish on Top Healthcare Picks